Revvity Is a Great Business Trading Like It's Already a Winner

# Revvity Is a Great Business Trading Like It's Already a Winner

Let's get the obvious out of the way: Revvity (NYSE: RVTY) has been one of the more impressive stories on the diagnostics tape this year. From about $97 at the start of 2026, it ripped to a fresh 52-week high near $151 — up roughly 57% year-to-date and nearly 66% over the trailing twelve months. That's not noise. That's a company the market has decided it likes, and likes a lot.

But here's the thing that keeps me up at night about a name like this, and it's never the business — it's the price.

You're Paying Up for Perfection, and Then Some

The fundamentals backing this move are genuinely not garbage. Revvity's Q2 results showed gross margins expanding to 57.1% and operating margins climbing to 12.0%, up from 10.7% the prior quarter. Free cash flow held up at nearly $181 million on the quarter. The thesis is real: a shift toward software (Signals SaaS), reagents, and consumables is supposed to lift the operating-margin baseline through 2026, and the instrument backlog is healthy. Add in the Human Cell Design acquisition for metabolic disease research and the new CE-IVDR T1D screening kit in Europe, and you've got an actual growth story, not a multiple pump.

So why do I keep staring at the valuation like it personally insulted me?

Because Revvity is trading at roughly 72x trailing earnings and 26x forward earnings, with a PEG of 3.00. The sell-side consensus target sits somewhere in the low $120s — MarketBeat pegs it near $116, S&P Global around $129, and the median across providers near $126. At $151, the stock is trading above every single target on the board, by double digits. The market isn't pricing a turnaround here. It's pricing a decade of flawless execution, zero missteps, and a China story that works out exactly as written.

That's not a sell signal. It's a humble signal.

The Tape Is Running Away from the Tape

Let's talk mechanics, because this matters more than most people realize. The stock broke out of a long consolidation near $97–104 and then went nearly vertical from roughly $112 to $151. The 14-day RSI is sitting at nearly 69 — approaching overbought, not there yet, but close. The stock is 7.5% above its 20-day average, 18.5% above its 50-day, and 42.6% above its 200-day.

When a stock is that far ahead of its own moving averages, it hasn't stopped being an uptrend. It's just become an extended one. The kind that whips patient sellers out of positions with a single afternoon drop.

And the sentiment? Retail sentiment on StockTwits is 100% bullish with a fresh-52-week-high euphoria tone. That is, without exception, a contrarian warning sign. When everyone who could be bought is already bought, who's left to buy?

The Analysts Are Telling You What to Think

There's a reason the consensus is "Hold." In the last couple of months, analysts have been quietly dialing back:

• RBC Capital initiated at Sector Perform with a $135 target, explicitly citing slowing growth and rising competition.
• UBS and Goldman both landed at Neutral/Hold with $140 targets.
• Bernstein held Hold at $120.
• CFRA downgraded from Buy to Hold.
• KeyBanc is the outlier, blasting its target to $165 on Overweight.

That's a wide dispersion — targets range from the low $90s to the $165s — which really just means nobody agrees the stock is cheap. Even the bull with a $165 target has to earn the other 10% from here.

One thing worth flagging: insider activity has been mildly negative, with CFO Max Krakowiak selling around $236K in September. Not a screaming red flag, but executives don't sell when they're bored.

So What's the Play?

Here's my honest read: Revvity is a high-quality business at a high price, trading in a market that's increasingly risk-averse. That combination deserves respect in both directions.

I am not chasing a stock that's up 66% in a year, sitting at 72x earnings, with an RSI near overbought and a wall of analysts telling me the easy money's made. Chasing euphoria is how good companies make you feel bad about owning great ones.

But I'm not shorting it either. The margin expansion is real, the cash flow is real, and the AI-driven diagnostics demand isn't a fiction. If I wanted in, I'd want to own it on weakness, not on strength. The logical shelf to buy — the old breakout base that's now turned to support — sits around the $122–124 zone. Below that, the $104 level becomes interesting. Above $155–160, you're paying up against the 52-week high for a stock everyone's already told you is rich.

And there's a catalyst coming: Q3 earnings on November 3, pre-market. That's roughly a month out. If you're going to hold through that, you better believe you're positioned for both the beat and the "good news isn't enough" drop — which is exactly the move a stretched multiple is most vulnerable to.

The Bottom Line

Revvity proved it's a business with a future. It did not prove the current price is a bargain. When the tape runs this far ahead of valuation, ahead of analysts, and ahead of its own insiders, you don't have to be right to make money — you just have to be patient.

Buy strength when it's cheap. Trim into euphoria when it's not. And for the love of compounding, don't marry a stock just because it's been a good ride.